Abeona Therapeutics, Inc. Stock

$6.47

2.71% today

Nasdaq, Jul 25, 08:46 pm CET

ISIN

US00289Y1073

Symbol

ABEO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Abeona Therapeutics, Inc. Stock price

$6.65

-65.35 90.76% 5Y

Nasdaq, Closing price Thu, Jul 24 2025

-0.06 0.89%

ISIN

US00289Y1073

Symbol

ABEO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$340.2m

Enterprise Value

$275.3m

Net debt

positive

Cash

$84.2m

Shares outstanding

49.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | 13.3

EV/Sales

- | 10.8

EV/FCF

negative

P/B

8.2

Financial Health

Equity Ratio

40.4%

Return on Equity

-144.8%

ROCE

-85.5%

ROIC

Debt/Equity

0.5

Financials (TTM | estimate)

Revenue

$0.0 | $25.6m

EBITDA

$-66.6m | -

EBIT

$-69.6m | $-54.5m

Net Income

$-44.2m | $-20.8m

Free Cash Flow

$-63.0m

Growth (TTM | estimate)

Revenue

-100.0% | -

EBITDA

-41.5% | -

EBIT

-40.9% | 15.1%

Net Income

42.4% | 67.4%

Free Cash Flow

-55.0%

EPS

$-0.9

FCF per Share

$-1.3

Short interest

17.4%

Employees

136

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Abeona Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

??

12 Analysts have issued a Abeona Therapeutics, Inc. forecast:

11x Buy

92%

More details on Analyst Estimates Including Price Targets

12 Analysts have issued a Abeona Therapeutics, Inc. forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Abeona Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	33 33	47% 47% -
- Research and Development Expense	37 37	23% 23% -
EBITDA	-67 -67	42% 42% -
- Depreciation and Amortization	3 3	28% 28% -
EBIT (Operating Income) EBIT	-70 -70	41% 41% -
Net Profit	-44 -44	42% 42% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Abeona Therapeutics, Inc. Stock News

Neutral

GlobeNewsWire

●

10 days ago

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

- Lucile Packard Children's Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics ® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 - - ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - CLEVELAND,...

Neutral

PRNewsWire

●

11 days ago

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

MINNEAPOLIS , July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics® (NASDAQ: ABEO). Throughout...

Neutral

GlobeNewsWire

●

23 days ago

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Cash resources totaled approximately $225 million as of June 30, 2025 Cash resources totaled approximately $225 million as of June 30, 2025

More Abeona Therapeutics, Inc. News

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Head office	United States
CEO	Vishwas Seshadri
Employees	136
Founded	1974
Website	abeonatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now